{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-22-013758","form_type":"8-K","ticker":"ABSI","cik":"0001672688","company_name":"Absci Corp","filed_at":"2022-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:04:01.734752+00:00","generated_at":"2026-06-25T21:04:49.400275+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Absci Q1 net loss $29.5M; cash $226M; signs Merck collaboration worth up to $610M","bullets":["Net loss of $29.5M in Q1 2022 vs $11.0M in Q1 2021; R&D expense $15.8M, SG&A $10.9M.","Cash and equivalents $226.0M as of March 31, 2022, sufficient to fund operations through end of 2024.","Entered Merck collaboration for Bionic Enzyme generation; potential $610M in upfront and milestones plus royalties.","Unveiled AI models for antibody affinity prediction and naturalness scoring; partnered with NVIDIA.","Reiterates guidance of at least 8 new Active Programs in 2022 (60% YoY growth); 3 signed year-to-date."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-22-013758","json":"https://secwatch.observer/filing/0001628280-22-013758.json","markdown":"https://secwatch.observer/filing/0001628280-22-013758.md","text":"https://secwatch.observer/filing/0001628280-22-013758.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1672688/000162828022013758/0001628280-22-013758-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1672688/000162828022013758/absc-20220511.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T21:04:49.400275+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}